Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Cytos Biotechnology AG |
---|---|
Information provided by: | Cytos Biotechnology AG |
ClinicalTrials.gov Identifier: | NCT00306553 |
The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine.
Condition | Intervention | Phase |
---|---|---|
Malignant Melanoma |
Biological: CYT004-MelQbG10 |
Phase II |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Switzerland | |
Dept. of Oncology, USZ | |
Zuerich, Switzerland, 8091 | |
Dept. of Dermatology, USZ | |
Zuerich, Switzerland, 8091 |
Principal Investigator: | Alexander Knuth, MD | Dept. of Oncology, Univerity Hospital Zuerich, CH |
Study ID Numbers: | CYT004-MelQbG10 03 |
Study First Received: | March 23, 2006 |
Last Updated: | September 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00306553 History of Changes |
Health Authority: | Switzerland: Swissmedic |
Neuroectodermal Tumors Nevus, Pigmented Neoplasms, Germ Cell and Embryonal Neuroepithelioma |
Nevus Neuroendocrine Tumors Melanoma |
Neuroectodermal Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal |
Neoplasms, Nerve Tissue Nevi and Melanomas Neuroendocrine Tumors Melanoma |